Archive for November 16th, 2010

P!nk Tells Ellen: I’m Pregnant!

P!nk says she “worked” for the pregnancy and that it was no accident. She also shares that the doctor thinks that the baby is a girl.

When it comes to her previously on-again, off-again relationship with Carey, she tells Ellen, “I never had anything in my life that I didn’t work hard for and my relationship is that. We worked really hard and we had our little meltdowns, a couple of them, and … we both needed to do that and come back together. It’s just yummy.”

Tune in to “The Ellen DeGeneres Show” on November 17 for the full interview




Read Full Post »

Florida: Greyhound Racing Has Got to Go!

This was in my business email sharing on here:

Dear Florida Advocates,

You are probably aware of the shocking animal cruelty case in Ebro, where more than 30 racing Greyhounds were found dead in late October. Sadly, this is not the first such instance of large-scale cruelty to racing dogs in Florida, one of only seven states in the nation where Greyhound racing still exists.

Greyhound racing is a dying sport—but it’s not dying fast enough in Florida, which is home to 13 tracks. This exploitive and inhumane form of entertainment has been banned by many states, including New Hampshire, Massachusetts, Rhode Island, North Carolina and Virginia. Florida should be next.

Please play an active role in changing your state’s law and spare thousands of Greyhounds from horrible futures as track dogs.

What You Can Do
Please urge the Florida State Legislature to take up this issue when it convenes in March. Visit the ASPCA Advocacy Center online to send an email to your state senator and representative asking them to take decisive steps in 2011 to ban Greyhound racing in Florida.

Thank you for your help and support, Florida!



Read Full Post »

Eisai Inc. announced that the United States Food and Drug Administration (FDA) has approved Halaven™ (eribulin mesylate) Injection for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Prior therapy should have included two common chemotherapy treatments, an anthracycline and a taxane, for early or advanced breast cancer. Discovered and developed by Eisai, Halaven is a non-taxane, microtubule dynamics inhibitor that is a synthetic analogue of halichondrin B, a product isolated from the marine sponge Halichondria okadai.

“Many women with metastatic breast cancer see their disease progress after receiving multiple therapies,” said Linda Vahdat, M.D., Professor of Medicine, Division of Hematology & Medical Oncology at the Iris Cantor Women’s Health Center at New York-Presbyterian Hospital/Weill Cornell Medical Center in New York City. “Now, with the approval of Halaven, we can offer a new option that has been shown to improve survival in women with metastatic disease.”



The FDA approval of Halaven is based on results from the pivotal Phase III clinical study EMBRACE (Eisai Metastatic Breast Cancer Study Assessing Physician’s Choice Versus Eribulin), which showed that patients treated with Halaven survived a median of 2.5 months longer than patients who received a single-agent therapy chosen by their physician (Treatment of Physician’s Choice). Overall survival was 13.12 months with Halaven versus 10.65 months with TPC (p=0.041). In an updated survival analysis, conducted when 77 percent of events had been observed, the result was consistent with the primary analysis.

The most common side effects (incidence ≥ 25 percent) reported by patients receiving Halaven were neutropenia (low white blood cells), anemia (low red blood cells), asthenia/fatigue (weakness/tiredness), alopecia (hair loss), peripheralneuropathy (numbness, tingling or burning in the hands and feet), nausea andconstipation. The most common serious side effects reported in patients receiving Halaven were neutropenia with or without fever (four percent and two percent, respectively). Severe weakness/tiredness occurred in 10 percent of patients receiving Halaven. The most common side effect resulting in discontinuation of treatment with Halaven was peripheral neuropathy (five percent).

“The FDA approval of Halaven is significant news for the metastatic breast cancer community in an area of unmet medical need,” said Lonnel Coats, President & CEO, Eisai Inc.

Read Full Post »

The Walking Dead:

This one so far is a damn good show.

Read Full Post »

Anna Torv

Read Full Post »